findmyKOL
Clinical trialNCT05300048TerminatedPhase 1Interventional

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

SponsorFaeth TherapeuticsEnrollment34Advanced Solid TumorPIK3CA MutationPTEN Loss of Function Mutation
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • Pacific Cancer Specialists

    Anaheim, California, United States

  • Valkyrie Clinical Trials

    Los Angeles, California, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, United States

  • Community Health Network, Inc.

    Indianapolis, Indiana, United States

  • Mayo Clinic - Rochester

    Rochester, Minnesota, United States

  • New Jersey Cancer Care, Pa

    Belleville, New Jersey, United States

  • Englewood Health

    Englewood, New Jersey, United States

  • Northwell Health

    Lake Success, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • East Carolina University

    Greenville, North Carolina, United States

  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, United States

  • Avera Cancer Institute

    Sioux Falls, South Dakota, United States

  • Baptist Hospitals of Southeast Texas

    Beaumont, Texas, United States

  • Oncology Consultants, Pa

    Houston, Texas, United States

  • Lumi Research

    Kingwood, Texas, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Paclitaxel →Serabelisib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Apr 2022
Primary completion
30 Apr 2025
Completion
30 Apr 2025
Last update posted
30 Apr 2026
Registered enrollment
34
Registry id
NCT05300048
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.